This multi-centre point prevalence study reports on antimicrobial dosing patterns, including dose, mode of administration and type of infection, in 37 Australian and New Zealand intensive care units. Of 422 patients admitted to an intensive care unit on 8 May 2007, 195 patients (46%) received antimicrobial treatment, 123 patients (29%) received no antimicrobials and 104 patients (25%) received prophylactic antimicrobials only. Dosing data were available for 331 antimicrobials used to treat 225 infections in 193 patients. Respiratory (40%), abdominal (13%) and blood stream (12%) infections were most common. For adult patients, ticarcillin/clavulanate (23% or 40/177), meropenem (20% or 35/177) and vancomycin (18% or 32/177) were the most frequently used antibiotics; vancomycin was most commonly used in children (31% or 5/16). The majority of antimicrobials were administered as bolus doses or infusions of less than two hours (98% or 317/323); only six patients received extended or continuous infusions. The mode of administration was unknown in eight cases (4.1%). The total defined daily dose for adult patients receiving antimicrobial therapy was 2051 defined daily doses per 1000 patient days. Our results confirm that the use of continuous infusions remains rare, despite increased interest in continuous infusions for time-dependent antibiotics.
Antimicrobial (antibiotic, antifungal and antiviral) therapy remains the mainstay of treatment for critically ill patients with clinically significant infection. In the intensive care unit (ICU), sepsis occurs in 20 to 38% of patients 1, 2 , with a total of 45% of prevalent patients found to have infection in the European Prevalence of Infection in Intensive Care (EPIC) study 3 and 51% in a subsequent global study 4 . Nosocomial infection and antimicrobial resistance rates in the ICU are also much higher than in the general hospital or community setting 5 . The resultant high utilisation of antibiotics in the ICU requires optimal antibiotic control measures to maximise efficacy, reduce cost and minimise levels of antimicrobial resistance 6 . In addition, physiological changes and varying antibiotic kill characteristics need to be taken into consideration to determine doses and regimens specific to critically ill patients 7 .
The importance of accurate and contemporaneous information on antibiotic utilisation in the ICU is well recognised [8] [9] [10] . In Australia and New Zealand, few studies have explored antibiotic dosing practices in the ICU [11] [12] [13] [14] . The aim of the present study was to identify antibiotic dosing patterns from a multicentre point prevalence study (EPIC II), involving Australian and New Zealand ICUs 4 .
MATERIALS AND METHODS
Australian and New Zealand ICUs participating in the EPIC II study 4 were invited to complete an additional antibiotic utilisation form providing dosage information for antibiotics used in all patients in the respective units on 8 May 2007. One form per patient was completed and included information on patient weight, antibiotic dose, frequency, mode of administration and type of infection: antibiotic dosing for prophylactic purposes was not explored.
Reported antifungal and antiviral treatment was included in the analysis. Clinical infection, with or without corresponding microbiological evidence, was defined as probable or possible infection based on definitions by the International Sepsis Forum with adjudication by the attending physician 4, 15 . Treatment commenced for microbiological evidence of infection in the absence of clinical signs was also included. Ethics approval was obtained from each of the participating institutions. Dose (g) was multiplied by frequency of administration to give a prescribed daily dose (PDD). A mean PDD for adult patients (age ≥15 years) is reported. Weight adjusted PDD (A-PDD) is reported in mg/kg/day. Missing weights in eight patients (all >20 years of age) were imputed using the mean weight by gender for patients 20 years or older (82 kg for males and 74 kg for females). A reference defined daily dose (R-DDD) was obtained for each antibiotic from the World Health Organization Collaborating Centre for Drug Statistics Methodology (http://www.whocc.no/ atcddd/). The R-DDD is a fixed unit of measurement, based on the average maintenance dose per day for a drug used for its main indication in adults, which allows for comparisons in drug consumption over time and between population groups. The PDD was divided by the R-DDD to give a calculated comparative measure of antibiotic utilisation in defined daily dose units (C-DDD). For patients receiving non-prophylactic antibiotics, the proportion of patients receiving a particular antibiotic was multiplied by the C-DDD and converted to defined daily doses (DDD) per 1000 patient days (C-DDD/1000). Statistical analysis was conducted using SPSS 15.0 (SPSS Inc., Chicago, IL, USA).
RESULTS

Study population
Thirty-seven Australian and New Zealand ICUs, including five paediatric units, submitted an antibiotic utilisation form (or indicated antibiotic usage) on a total of 422 patients (median per site=10; range 2 to 28). Of these, 195 patients (46%) received antimicrobial therapy to treat an identified infection, 123 patients (29%) received no antimicrobials and 104 patients (25%) received prophylactic antimicrobials only. Infection type is listed in Table 1 .
Of the 195 patients receiving treatment antimicrobials, the median age was 60 (interquartile range 45 to 74) with 16 patients <15 years of age; 59% were male (101/172, missing gender=23). Seventeen percent had a solid organ or haematological neoplasm (29/175), 16% had chronic obstructive pulmonary disease (27/175), 8% had chronic renal failure (14/175) and 5.1% had New York Heart Association Class III to IV heart failure (9/175); comorbid status was missing for 20 patients. Fourteen patients (8%) were receiving steroid therapy or immunosuppression. ICU mortality was 17% (28/162, missing outcome=33) and hospital mortality was 26% (38/144, missing outcome=51).
Antimicrobial treatment
Antimicrobial dosing data was available for 331 antimicrobials used to treat 225 infections in 193 patients; two patients (from Table 1 ) were excluded due to incomplete dosing information. The median number of antimicrobial agents per patient was two, with a maximum of five. The most common mode of administration was bolus administration or infusions of less than two hours (317/323 or 98.1%); mode of administration was not specified for eight patients. Table 3 . Table 4 lists frequency of use and weight adjusted PDD for paediatric patients.
DISCUSSION
This multi-centre point prevalence study provides recent information on antibiotic and antifungal use in an Australian and New Zealand ICU population. While the sample is not representative of all ICUs, the sample did include 37 of 52 ICUs and approximately half of patients identified with an infection in the EPIC II study from Australia and New Zealand 4 .
Antimicrobial therapy was most common for the treatment of respiratory and abdominal infections, with one-half and one-sixth of patients receiving antimicrobial therapy for these indications, respectively. Similar proportions were found in two year-long surveillance studies of antibiotic use in the ICUs of university hospitals in The Netherlands and Denmark 8, 16 .
Ticarcillin/clavulanate, vancomycin and meropenem were identified as the most frequently used antibiotics amongst adult patients, followed by piperacillin/tazobactam, ceftriaxone and metronidazole. A multicentre prospective study in 1998 identified four of the same top six antibiotics used to treat infection 11 . However, ticarcillin/ clavulanate was used more frequently in the current study, while gentamicin was notably absent from the top six. Similarly, meropenem did not feature in the 1998 study, while the reverse was true for cefotaxime. Of the antifungal agents, fluconazole was three times more frequently used than the other antifungals (voriconazole, amphotericin and caspofungin) combined. Antiviral usage (acyclovir) was reported in only two cases of central nervous system infection with one case of valacyclovir use (infection not specified). The representativeness of reported antifungal and antiviral therapy in the participating sites is however unknown, given information on all antimicrobial therapy was not specifically asked for.
While there has been increased interest in the value of continuous antibiotic infusions for socalled time-dependent drugs, such as β-lactams and glycopeptides 17 , we found the use of continuous infusions to be rare. The prevalence of infusions in the β-lactam antibiotic class (1.8%) was similar to that observed in a case vignette survey (2.5%) of prescribing patterns in Australian and New Zealand intensivists 18 . We found that for 37 cases involving vancomycin therapy, all but one was administered over less than two hours (2.7% were continuous infusions), while the survey of prescribing practice in 2009 indicated 8.5% of cases would be administered as continuous infusion 18 . The authors believe that continuous infusions are vastly under-utilised for timedependent antibiotics. Good evidence is currently available for continuous infusion of vancomycin 19 .
No difference in clinical cure or survival has been observed between continuous β-lactam infusion and bolus dosing with the use of a higher antibiotic dose in the bolus administration group 20 . However, definitive outcome data on the use of continuous infusions for β-lactam antibiotics with dosing equivalence to bolus administration is still required 21 and a large prospective Australian and New Zealand study is proposed. ICU antibiotic usage has previously been reported to range from 1351 and 2191 DDDs per 1000 patientdays in eight Australian ICUs 12 . We found that total antimicrobial use, while only representative of the subgroup of adult patients receiving antimicrobial therapy for clinical or microbiological evidence of infection, was 2051 DDDs per 1000 patient-days. After antifungal and antiviral therapy was excluded, antibiotic usage in the remaining patients was 1861 DDDs per 1000 patient-days, which is mid-range of this previous report. While overall antibiotic consumption appears appropriate, comparison of the mean PDD for individual antibiotics suggests some marked differences with Australian Therapeutic Guidelines 22 . In particular, the PDD of ceftriaxone and metronidazole was >125% of the recommended daily dose, while the PDD of vancomycin, gentamicin and flucloxacillin was <75% of the recommended daily dose, or base dose of 7 mg/kg in the case of gentamicin.
This study has a number of limitations. Completion of the antibiotic utilisation form was at the discretion of the participating sites and there was some variation between sites as to whether information was available for patients on prophylactic antibiotics and those not receiving antibiotics at all. Therefore we were unable to calculate antibiotic usage in DDDs per 1000 patient-days for all patients admitted to the participating ICUs on 8 May 2007. The DDDs per 1000 patient-days reported here may overestimate total ICU antimicrobial use when uncomplicated or routine post-surgical admissions are included.
In conclusion, this study provides point prevalence estimates of antimicrobial usage in Australian and New Zealand ICUs. Our data confirms that use of continuous infusions remain rare, despite increased interest and supportive evidence for continuous infusion of time-dependent antibiotics. The low uptake of continuous infusions into clinical practice that we observed supports the feasibility of a randomised controlled trial of continuous β-lactam infusion compared with dose equivalent bolus administration in Australia and New Zealand. In addition, as prescribing practices evolve with the introduction of new therapeutic measures and changing resistance patterns, we recommend that future multi-centre studies on antibiotic utilisation are undertaken to identify areas where prescribing patterns lag behind evidence-based guidelines.
